Bladder Cancer

Photocure launches Cysview Commercial Operations in Canada

Reno, Nevada ( -- Photocure ASA (Photocure, PHO: OSE) today announces the start of its Cysview® sales, marketing and distribution operations in the Canadian market. In August 2021 Photocure had reached an agreement with BioSyent Pharma Inc. (“BioSyent”) to reacquire the marketing and distribution rights to Cysview in Canada, effective on January 1st, 2022.

Contemporary treatment patterns and outcomes of sarcomatoid bladder cancer: Beyond the Abstract

In 2016, 750,000 bladder cancer survivors are estimated to live in the United States alone and over 75,000 new cases will be diagnosed.1,2 The vast majority are urothelial tumors however a small proportion of these will be variant histologies. Sarcomatoid carcinoma (SaC) is such a subtype and is estimated to represent 0.3% of all urothelial cancers.3 Much of our knowledge about this disease is derived from case studies or single-institution reports of which have totaled fewer than 100 cases in the last several decades.4-7

Intravesical rad-IFNα/Syn3 for Patients with High-Grade, Bacillus Calmette-Guérin (BCG) Refractory or Relapsed Non-Muscle Invasive Bladder Cancer: A Phase II Randomized Study

Many patients with high-risk non–muscle-invasive bladder cancer (NMIBC) are either refractory to bacillus Calmette-Guerin (BCG) treatment or may experience disease relapse. We assessed the efficacy and safety of recombinant adenovirus interferon alfa with Syn3 (rAd–IFNα/Syn3), a replication-deficient recombinant adenovirus gene transfer vector, for patients with high-grade (HG) BCG-refractory or relapsed NMIBC.
email news signup